Amedeo Smart

Free Medical Literature Service

 

Amedeo

Malignant Lymphoma
  Free Subscription

Articles published in
J Clin Oncol
    March 2024
  1. BINKLEY MS, Flerlage JE, Savage KJ, Akhtar S, et al
    International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    J Clin Oncol. 2024 Mar 26:JCO2301655. doi: 10.1200/JCO.23.01655.
    >> Share

  2. MEHTA-SHAH N, Horwitz SM
    Failing Forward in Peripheral T-Cell Lymphoma.
    J Clin Oncol. 2024 Mar 26:JCO2302658. doi: 10.1200/JCO.23.02658.
    >> Share

    February 2024
  3. CAMUS V, Thieblemont C, Gaulard P, Cheminant M, et al
    Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
    J Clin Oncol. 2024 Feb 16:JCO2301687. doi: 10.1200/JCO.23.01687.
    >> Share

  4. NEPPELENBROEK SIM, Geurts YM, Aleman BMP, Lugtenburg PJ, et al
    Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma.
    J Clin Oncol. 2024 Feb 15:JCO2301386. doi: 10.1200/JCO.23.01386.
    >> Share

  5. COOPER A, Tumuluru S, Kissick K, Venkataraman G, et al
    CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition.
    J Clin Oncol. 2024;42:467-480.
    >> Share

    January 2024

  6. Erratum: The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.
    J Clin Oncol. 2024 Jan 11:JCO2302698. doi: 10.1200/JCO.23.02698.
    >> Share

  7. KAHL BS, Jegede OA, Peterson C, Swinnen LJ, et al
    Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.
    J Clin Oncol. 2024 Jan 9:JCO2301912. doi: 10.1200/JCO.23.01912.
    >> Share

    December 2023
  8. AOKI T, Jiang A, Xu A, Yin Y, et al
    Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.
    J Clin Oncol. 2023 Dec 19:JCO2301115. doi: 10.1200/JCO.23.01115.
    >> Share

  9. SARKOZY C, Thieblemont C, Oberic L, Moreau A, et al
    Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
    J Clin Oncol. 2023 Dec 18:JCO2301586. doi: 10.1200/JCO.23.01586.
    >> Share

  10. POTT C, Jurinovic V, Trotman J, Kehden B, et al
    Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.
    J Clin Oncol. 2023 Dec 14:JCO2300838. doi: 10.1200/JCO.23.00838.
    >> Share

  11. WANG M, Siddiqi T, Gordon LI, Kamdar M, et al
    Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma (MCL): Primary Analysis of the MCL Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
    J Clin Oncol. 2023 Dec 10:101200JCO2302214. doi: 10.1200/JCO.23.02214.
    >> Share

  12. NOERENBERG D, Briest F, Hennch C, Yoshida K, et al
    Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes.
    J Clin Oncol. 2023 Dec 6:JCO2301053. doi: 10.1200/JCO.23.01053.
    >> Share

    November 2023
  13. HOSTER E, Delfau-Larue MH, Macintyre E, Jiang L, et al
    Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.
    J Clin Oncol. 2023 Nov 22:JCO2300899. doi: 10.1200/JCO.23.00899.
    >> Share

  14. KELLY KM, Friedberg JW
    Classic Hodgkin Lymphoma in Adolescents and Young Adults.
    J Clin Oncol. 2023 Nov 20:JCO2301799. doi: 10.1200/JCO.23.01799.
    >> Share

  15. FEDERICO M, Fortpied C, Stepanishyna Y, Gotti M, et al
    Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
    J Clin Oncol. 2023 Nov 15:JCO2301745. doi: 10.1200/JCO.23.01745.
    >> Share

    October 2023
  16. LUMINARI S, Fossa A, Trotman J, Molin D, et al
    Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial.
    J Clin Oncol. 2023 Oct 26:JCO2301177. doi: 10.1200/JCO.23.01177.
    >> Share

  17. IACOBONI G, Navarro V, Martin-Lopez AA, Rejeski K, et al
    Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.
    J Clin Oncol. 2023 Oct 24:JCO2301097. doi: 10.1200/JCO.23.01097.
    >> Share

  18. LEWIS KL, Jakobsen LH, Villa D, Smedby KE, et al
    High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.
    J Clin Oncol. 2023 Oct 5:JCO2300365. doi: 10.1200/JCO.23.00365.
    >> Share

    July 2023
  19. ZINZANI PL, Mayer J, Flowers CR, Bijou F, et al
    ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
    J Clin Oncol. 2023 Jul 28:101200JCO2300775. doi: 10.1200/JCO.23.00775.
    >> Share


  20. Erratum: Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
    J Clin Oncol. 2023 Jul 14:JCO2301377. doi: 10.1200/JCO.23.01377.
    >> Share

    June 2023
  21. HILTON LK, Ngu HS, Collinge B, Dreval K, et al
    Relapse Timing Is Associated With Distinct Evolutionary Dynamics in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2023 Jun 15:JCO2300570. doi: 10.1200/JCO.23.00570.
    >> Share

    May 2023

  22. Erratum: Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.
    J Clin Oncol. 2023 May 26:JCO2300952. doi: 10.1200/JCO.23.00952.
    >> Share

  23. WANG ML, Jurczak W, Zinzani PL, Eyre TA, et al
    Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma.
    J Clin Oncol. 2023 May 16:101200JCO2300562. doi: 10.1200/JCO.23.00562.
    >> Share

    April 2023
  24. CARTRON G, Bachy E, Tilly H, Daguindau N, et al
    Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
    J Clin Oncol. 2023 Apr 18:JCO2202327. doi: 10.1200/JCO.22.02327.
    >> Share


  25. Erratum: Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice.
    J Clin Oncol. 2023 Apr 11:JCO2300633. doi: 10.1200/JCO.23.00633.
    >> Share

    March 2023
  26. HUANG H, Tao R, Hao S, Yang Y, et al
    Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study.
    J Clin Oncol. 2023 Mar 30:JCO2202367. doi: 10.1200/JCO.22.02367.
    >> Share

  27. DAVIES AJ, Barrans S, Stanton L, Caddy J, et al
    Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up.
    J Clin Oncol. 2023 Mar 27:JCO2300033. doi: 10.1200/JCO.23.00033.
    >> Share

  28. GOUNDER MM, Bauer TM, Schwartz GK, Weise AM, et al
    A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
    J Clin Oncol. 2023;41:1714-1724.
    >> Share

  29. MUTTER JA, Alig SK, Esfahani MS, Lauer EM, et al
    Circulating Tumor DNA Profiling for Detection, Risk Stratification, and Classification of Brain Lymphomas.
    J Clin Oncol. 2023;41:1684-1694.
    >> Share

    February 2023
  30. WANG Y, Jain P, Locke FL, Maurer MJ, et al
    Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
    J Clin Oncol. 2023 Feb 8:JCO2201797. doi: 10.1200/JCO.22.01797.
    >> Share

    January 2023
  31. GROMMES C
    Circulating Tumor DNA in the Blood: A New Frontier in Primary CNS Lymphoma?
    J Clin Oncol. 2023 Jan 20:JCO2202605. doi: 10.1200/JCO.22.02605.
    >> Share

  32. MCLAUGHLIN P, Grillo-Lopez AJ, Link BK, Levy R, et al
    Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.
    J Clin Oncol. 2023;41:154-162.
    >> Share


  33. JCO Flashback: Evaluating Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed B-cell Lymphoma (1998).
    J Clin Oncol. 2023;41:153.
    >> Share

    December 2022
  34. THIEBLEMONT C, Phillips T, Ghesquieres H, Cheah CY, et al
    Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
    J Clin Oncol. 2022 Dec 22:JCO2201725. doi: 10.1200/JCO.22.01725.
    >> Share

  35. LOWE EJ, Reilly AF, Lim MS, Gross TG, et al
    Crizotinib in Combination With Chemotherapy for Pediatric Patients With ALK+ Anaplastic Large-Cell Lymphoma: The Results of Children's Oncology Group Trial ANHL12P1.
    J Clin Oncol. 2022 Dec 19:JCO2200272. doi: 10.1200/JCO.22.00272.
    >> Share

  36. NASTOUPIL LJ, Bartlett NL
    Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2022 Dec 12:JCO2201848. doi: 10.1200/JCO.22.01848.
    >> Share

  37. BROCKELMANN PJ, Buhnen I, Meissner J, Trautmann-Grill K, et al
    Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
    J Clin Oncol. 2022 Dec 12:JCO2202355. doi: 10.1200/JCO.22.02355.
    >> Share

  38. RODDAY AM, Parsons SK, Upshaw JN, Friedberg JW, et al
    The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium.
    J Clin Oncol. 2022 Dec 10:JCO2202473. doi: 10.1200/JCO.22.02473.
    >> Share

  39. MERLI M, Rattotti S, Spina M, Re F, et al
    Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.
    J Clin Oncol. 2022;40:4060-4070.
    >> Share

  40. HERMINE O, Jiang L, Walewski J, Bosly A, et al
    High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
    J Clin Oncol. 2022 Dec 5:JCO2201780. doi: 10.1200/JCO.22.01780.
    >> Share

    November 2022
  41. HILLMEN P, Eichhorst B, Brown JR, Lamanna N, et al
    Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
    J Clin Oncol. 2022 Nov 17:JCO2200510. doi: 10.1200/JCO.22.00510.
    >> Share

    October 2022
  42. VIJENTHIRA A, Kuruvilla J, Crump M, Jain M, et al
    Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk
    J Clin Oncol. 2022 Oct 31:JCO2200478. doi: 10.1200/JCO.22.00478.
    >> Share

  43. LACASCE AS, Dockter T, Ruppert AS, Kostakoglu L, et al
    Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).
    J Clin Oncol. 2022 Oct 21:JCO2200947. doi: 10.1200/JCO.22.00947.
    >> Share

  44. WONG FL, Lee JM, Leisenring WM, Neglia JP, et al
    Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
    J Clin Oncol. 2022 Oct 20:JCO2200574. doi: 10.1200/JCO.22.00574.
    >> Share

    September 2022
  45. RUBENSTEIN JL
    Primary CNS Lymphoma: Progress With Dose-Intensive Consolidation.
    J Clin Oncol. 2022 Sep 30:JCO2201337. doi: 10.1200/JCO.22.01337.
    >> Share

  46. FENSKE TS
    Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide.
    J Clin Oncol. 2022 Sep 28:JCO2201661. doi: 10.1200/JCO.22.01661.
    >> Share

  47. KAHL BS
    Management of Diffuse Large B-Cell Lymphoma: Are We Getting Smarter?
    J Clin Oncol. 2022 Sep 1:JCO2201501. doi: 10.1200/JCO.22.01501.
    >> Share

    August 2022
  48. WESTIN J, Davis RE, Feng L, Hagemeister F, et al
    Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
    J Clin Oncol. 2022 Aug 11:JCO2200597. doi: 10.1200/JCO.22.00597.
    >> Share

  49. DE VRIES S, Haaksma ML, Jozwiak K, Schaapveld M, et al
    Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma.
    J Clin Oncol. 2022 Aug 10:JCO2102613. doi: 10.1200/JCO.21.02613.
    >> Share

  50. MORSCHHAUSER F, Nastoupil L, Feugier P, Schiano de Colella JM, et al
    Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R(2)) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
    J Clin Oncol. 2022 Aug 10:JCO2200843. doi: 10.1200/JCO.22.00843.
    >> Share

    July 2022
  51. FORNECKER LM, Lazarovici J, Aurer I, Casasnovas RO, et al
    Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
    J Clin Oncol. 2022 Jul 22:JCO2101281. doi: 10.1200/JCO.21.01281.
    >> Share

  52. AMADOR C, Bouska A, Wright G, Weisenburger DD, et al
    Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice.
    J Clin Oncol. 2022 Jul 15:JCO2102707. doi: 10.1200/JCO.21.02707.
    >> Share

  53. HOUILLIER C, Dureau S, Taillandier L, Houot R, et al
    Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients Age 60 Years and Younger: Long-Term Results of the Randomized Phase II PRECIS Study.
    J Clin Oncol. 2022 Jul 14:JCO2200491. doi: 10.1200/JCO.22.00491.
    >> Share

  54. WANG Y, Cao J, Gu W, Shi M, et al
    Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
    J Clin Oncol. 2022;40:2246-2256.
    >> Share

  55. RUTHERFORD SC, Yin J, Pederson L, Perez Burbano G, et al
    Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials.
    J Clin Oncol. 2022 Jul 5:JCO2102301. doi: 10.1200/JCO.21.02301.
    >> Share

    June 2022
  56. MARTIN P, Cohen JB, Wang M, Kumar A, et al
    Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
    J Clin Oncol. 2022 Jun 28:JCO2102698. doi: 10.1200/JCO.21.02698.
    >> Share

  57. WANG M, Munoz J, Goy A, Locke FL, et al
    Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.
    J Clin Oncol. 2022 Jun 4:JCO2102370. doi: 10.1200/JCO.21.02370.
    >> Share

    April 2022
  58. CHANG A, Akhtar A, Linderman SL, Lai L, et al
    Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2022 Apr 18:JCO2200088. doi: 10.1200/JCO.22.00088.
    >> Share

  59. LAKHOTIA R, Melani C, Roschewski M, Wilson WH, et al
    Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?
    J Clin Oncol. 2022 Apr 4:JCO2102593. doi: 10.1200/JCO.21.02593.
    >> Share

    March 2022
  60. MIKHAEEL NG, Heymans MW, Eertink JJ, de Vet HCW, et al
    Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.
    J Clin Oncol. 2022 Mar 31:JCO2102063. doi: 10.1200/JCO.21.02063.
    >> Share

  61. MYERS RM, Taraseviciute A, Steinberg SM, Lamble AJ, et al
    Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
    J Clin Oncol. 2022;40:932-944.
    >> Share

  62. SHIBUSAWA M, Kusumi E, Murakami J, Tanimoto T, et al
    Response-Adapted Postinduction Strategy in Follicular Lymphoma.
    J Clin Oncol. 2022 Mar 11:JCO2102818. doi: 10.1200/JCO.21.02818.
    >> Share

  63. TEACHEY DT, Devidas M, Wood BL, Chen Z, et al
    Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
    J Clin Oncol. 2022 Mar 10:JCO2102678. doi: 10.1200/JCO.21.02678.
    >> Share

  64. WADHWA D
    Turning Point.
    J Clin Oncol. 2022;40:801-802.
    >> Share

    February 2022
  65. ADVANI AS, Moseley A, O'Dwyer KM, Wood BL, et al
    SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2022 Feb 14:JCO2101766. doi: 10.1200/JCO.21.01766.
    >> Share

  66. BUDDE LE, Assouline S, Sehn LH, Schuster SJ, et al
    Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
    J Clin Oncol. 2022;40:481-491.
    >> Share

    January 2022
  67. CASULO C
    Response-Adapted Therapy in Follicular Lymphoma: At the Threshold of a Precision Approach.
    J Clin Oncol. 2022 Jan 25:JCO2102477. doi: 10.1200/JCO.21.02477.
    >> Share

  68. LAGERLOF I, Fohlin H, Enblad G, Glimelius B, et al
    Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy.
    J Clin Oncol. 2022 Jan 25:JCO2102407. doi: 10.1200/JCO.21.02407.
    >> Share

  69. LOUARN N, Galicier L, Bertinchamp R, Lussato D, et al
    First Extensive Analysis of (18)F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in a Large Cohort of Patients With HIV-Associated Hodgkin Lymphoma: Baseline Total Metabolic Tumor Volume Affects Prognosis.
    J Clin Oncol. 2022 Jan 24:JCO2101228. doi: 10.1200/JCO.21.01228.
    >> Share

  70. GINE E, de la Cruz F, Jimenez Ubieto A, Lopez Jimenez J, et al
    Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
    J Clin Oncol. 2022 Jan 14:JCO2102321. doi: 10.1200/JCO.21.02321.
    >> Share

  71. CASASNOVAS RO, Bouabdallah R, Brice P, Lazarovici J, et al
    Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
    J Clin Oncol. 2022 Jan 6:JCO2101777. doi: 10.1200/JCO.21.01777.
    >> Share

    December 2021
  72. SHOUVAL R, Alarcon Tomas A, Fein JA, Flynn JR, et al
    Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy.
    J Clin Oncol. 2021 Dec 3:JCO2102143. doi: 10.1200/JCO.21.02143.
    >> Share

    November 2021
  73. MOSKOWITZ AJ
    Moving Beyond One Size Fits All for T-Cell Lymphoma.
    J Clin Oncol. 2021 Nov 29:JCO2102463. doi: 10.1200/JCO.21.02463.
    >> Share

  74. BACHY E, Camus V, Thieblemont C, Sibon D, et al
    Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
    J Clin Oncol. 2021 Nov 29:JCO2101815. doi: 10.1200/JCO.21.01815.
    >> Share

  75. JAIN P, Zhao S, Lee HJ, Hill HA, et al
    Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
    J Clin Oncol. 2021 Nov 19:JCO2101797. doi: 10.1200/JCO.21.01797.
    >> Share

    October 2021
  76. LUMINARI S, Manni M, Galimberti S, Versari A, et al
    Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study.
    J Clin Oncol. 2021 Oct 28:JCO2101234. doi: 10.1200/JCO.21.01234.
    >> Share

    September 2021
  77. BURKE GAA, Minard-Colin V, Auperin A, Alexander S, et al
    Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.
    J Clin Oncol. 2021 Sep 27:JCO2100920. doi: 10.1200/JCO.21.00920.
    >> Share

  78. FRANK MJ, Hossain NM, Bukhari A, Dean E, et al
    Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
    J Clin Oncol. 2021;39:3034-3043.
    >> Share

    August 2021
  79. BARTLETT NL
    Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress.
    J Clin Oncol. 2021 Aug 24:JCO2101552. doi: 10.1200/JCO.21.01552.
    >> Share

  80. CUTTER DJ, Ramroth J, Diez P, Buckle A, et al
    Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.
    J Clin Oncol. 2021 Aug 13:JCO2100408. doi: 10.1200/JCO.21.00408.
    >> Share

    June 2021
  81. OVLISEN AK, Jakobsen LH, Eloranta S, Kragholm KH, et al
    Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study.
    J Clin Oncol. 2021 Jun 25:JCO2100357. doi: 10.1200/JCO.21.00357.
    >> Share

  82. MOSKOWITZ AJ, Shah G, Schoder H, Ganesan N, et al
    Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.
    J Clin Oncol. 2021 Jun 25:JCO2101056. doi: 10.1200/JCO.21.01056.
    >> Share

  83. DEMEESTERE I, Racape J, Dechene J, Dupuis J, et al
    Gonadal Function Recovery in Patients With Advanced Hodgkin Lymphoma Treated With a PET-Adapted Regimen: Prospective Analysis of a Randomized Phase III Trial (AHL2011).
    J Clin Oncol. 2021 Jun 22:JCO2100068. doi: 10.1200/JCO.21.00068.
    >> Share

    May 2021
  84. SMITH SD, Gopal AK
    Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL.
    J Clin Oncol. 2021;39:1671-1673.
    >> Share

    April 2021
  85. ALIG S, Macaulay CW, Kurtz DM, Duhrsen U, et al
    Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
    J Clin Oncol. 2021 Apr 28:JCO2002573. doi: 10.1200/JCO.20.02573.
    >> Share

  86. KUMAR A, Casulo C, Advani RH, Budde E, et al
    Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
    J Clin Oncol. 2021 Apr 28:JCO2100108. doi: 10.1200/JCO.21.00108.
    >> Share

  87. SHAW BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, et al
    National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
    J Clin Oncol. 2021 Apr 27:JCO2003502. doi: 10.1200/JCO.20.03502.
    >> Share

  88. DAVIES AJ
    Precision Medicine in DLBCL: Are We There Yet?
    J Clin Oncol. 2021;39:1314-1316.
    >> Share

  89. SMITH SM
    Improving Survival and Predicting Toxicity in Older Patients With DLBCL: A Delicate Balance.
    J Clin Oncol. 2021;39:1193-1195.
    >> Share

  90. METZGER ML, Link MP, Billett AL, Flerlage J, et al
    Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.
    J Clin Oncol. 2021 Apr 7:JCO2003286. doi: 10.1200/JCO.20.03286.
    >> Share

  91. RAMER SJ
    This Is Not Happening.
    J Clin Oncol. 2021;39:1162-1164.
    >> Share

    February 2021
  92. HESLOP HE, Sharma S, Rooney CM
    Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.
    J Clin Oncol. 2021;39:514-524.
    >> Share

  93. AOKI T, Savage KJ, Steidl C
    Biology in Practice: Harnessing the Curative Potential of the Immune System in Lymphoid Cancers.
    J Clin Oncol. 2021;39:346-360.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016